- Home
- IFRX vs ICCC Comparison
IFRX vs ICCC Comparison
Compare IFRX & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- ICCC
- Stock Information
- Founded
- IFRX 2007
- ICCC 1982
- Country
- IFRX Germany
- ICCC United States
- Employees
- IFRX N/A
- ICCC N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- IFRX Health Care
- ICCC Health Care
- Exchange
- IFRX Nasdaq
- ICCC Nasdaq
- Market Cap
- IFRX 53.5M
- ICCC 57.4M
- IPO Year
- IFRX 2017
- ICCC 1987
- Fundamental
- Price
- IFRX $1.43
- ICCC $6.56
- Analyst Decision
- IFRX Strong Buy
- ICCC
- Analyst Count
- IFRX 5
- ICCC 0
- Target Price
- IFRX $7.40
- ICCC N/A
- AVG Volume (30 Days)
- IFRX 492.5K
- ICCC 15.6K
- Earning Date
- IFRX 11-07-2025
- ICCC 11-12-2025
- Dividend Yield
- IFRX N/A
- ICCC N/A
- EPS Growth
- IFRX N/A
- ICCC N/A
- EPS
- IFRX N/A
- ICCC 0.20
- Revenue
- IFRX $191,224.00
- ICCC $28,274,756.00
- Revenue This Year
- IFRX N/A
- ICCC N/A
- Revenue Next Year
- IFRX $1,216.24
- ICCC N/A
- P/E Ratio
- IFRX N/A
- ICCC $31.65
- Revenue Growth
- IFRX 54.36
- ICCC 21.75
- 52 Week Low
- IFRX $0.71
- ICCC $3.38
- 52 Week High
- IFRX $2.82
- ICCC $7.60
- Technical
- Relative Strength Index (RSI)
- IFRX 55.06
- ICCC 58.43
- Support Level
- IFRX $1.29
- ICCC $6.30
- Resistance Level
- IFRX $1.44
- ICCC $6.99
- Average True Range (ATR)
- IFRX 0.14
- ICCC 0.30
- MACD
- IFRX -0.00
- ICCC 0.06
- Stochastic Oscillator
- IFRX 48.84
- ICCC 69.06
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.